How big is Praxis Precision Medicines, Inc.?

As of Jun 18, Praxis Precision Medicines, Inc. has a market capitalization of 885.24 million and reported net sales of 8.12 million with a net profit of -212.57 million over the latest four quarters. Shareholder's funds are 445.45 million and total assets are 483.11 million as of Dec 24.

As of Jun 18, Praxis Precision Medicines, Inc. has a market capitalization of 885.24 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 8.12 million, while the sum of net profit for the same period is -212.57 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds of 445.45 million and total assets of 483.11 million.

What does Praxis Precision Medicines, Inc. do?

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders. It has a market cap of $885.24 million and reported a net profit loss of $69 million as of March 2025.

Overview:<BR>Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company engaged in developing therapies for central nervous system disorders characterized by neuronal imbalance, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>- Most recent Net Profit: -69 Million (Quarterly Results - Mar 2025)<BR>- Market-cap: USD 885.24 Million (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: NA (Loss Making)<BR>- Industry P/E: NA<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.74<BR>- Return on Equity: -48.40%<BR>- Price to Book: 2.02<BR><BR>Contact Details:<BR>- Address: 101 Main Street, #1210, Suite 1210, CAMBRIDGE MA: 02142<BR>- Tel: 1 617 9492220<BR>- Website: https://praxismedicines.com/

Should I buy, sell or hold Praxis Precision Medicines, Inc.?

Who are in the management team of Praxis Precision Medicines, Inc.?

As of March 2022, the management team of Praxis Precision Medicines, Inc. includes Mr. Kiran Reddy, who is the Co-Founder and Director of the company.

As of March 2022, the management team of Praxis Precision Medicines, Inc. includes Mr. Kiran Reddy, who serves as the Co-Founder and Director of the company.

Is Praxis Precision Medicines, Inc. overvalued or undervalued?

As of August 9, 2023, Praxis Precision Medicines, Inc. is considered risky and overvalued due to significant losses and poor financial metrics, underperforming the S&P 500 with a return of -23.83% compared to the index's 17.14%.

As of 9 August 2023, the valuation grade for Praxis Precision Medicines, Inc. has moved from does not qualify to risky, indicating increased uncertainty regarding its financial health. The company appears to be overvalued given its significant losses and poor financial metrics, including a Price to Book Value of 2.07, an EV to Sales ratio of 71.50, and a ROE of -48.40%. <BR><BR>In comparison to its peers, Ocular Therapeutix, Inc. has a more severe P/E ratio of -9.92 and an EV to EBITDA of -8.44, suggesting that both companies are struggling, but Praxis's ratios indicate a relatively less favorable position. Notably, over the past year, Praxis has underperformed against the S&P 500, with a return of -23.83% compared to the index's 17.14%, reinforcing the perception of overvaluation.

Is Praxis Precision Medicines, Inc. technically bullish or bearish?

As of October 24, 2025, Praxis Precision Medicines, Inc. has a mildly bullish technical trend, supported by bullish moving averages and Bollinger Bands, despite bearish RSI readings and long-term underperformance compared to the S&P 500.

As of 24 October 2025, the technical trend for Praxis Precision Medicines, Inc. has changed from bullish to mildly bullish. The weekly MACD indicates a bullish stance, while the monthly MACD is mildly bullish. However, the RSI readings are bearish for both weekly and monthly periods. The Bollinger Bands show a mildly bullish trend weekly and bullish monthly. Daily moving averages are bullish, but the KST is bullish weekly and mildly bearish monthly. Dow Theory indicates no trend weekly and mildly bullish monthly, while the OBV is bullish monthly but shows no trend weekly.<BR><BR>In terms of performance, the stock has returned 255.26% over the past month, significantly outperforming the S&P 500's 2.32% return, but it has underperformed over the longer term, with a 5-year return of -62.58% compared to the S&P 500's 95.99%. Overall, the current technical stance is mildly bullish, driven primarily by the moving averages and Bollinger Bands.